The optimal duration of oral anticoagulation after a first idiopathic venous thromboembolism is uncertain. Recent prospective observational studies show that D-dimer levels have a predictive value for the risk of recurrence. D-dimer testing may help in assessing the individual need for prolonged anticoagulation.
Introduction
Patients with a previous episode of symptomatic venous thromboembolism (VTE) have a relatively high risk for recurrent VTE that persists for many years. Prospective studies show that although the risk of recurrence is higher in the first 6-12 months after the initial event, it never falls to zero. Prandoni et al. [1] reported a cumulative incidence of recurrent VTE of 17.5%, 24.6% and 30.3% after 2, 5 and 8 years respectively. In a more recent population-based cohort study, Heit et al. [2] found an overall cumulative percentage of VTE recurrence of 12.9% and 30.4% at 1 and 10 years, respectively.
Risk factors and characteristics of patients
The risk of recurrent VTE is well known to be higher when the initial event is associated with a permanent triggering or predisposing cause rather than with a temporary triggering factor [3] . Carriers of antithrombin, protein C and protein S defects are more prone to develop recurrent thrombotic events than noncarriers [1] , as well as patients with homozygosity or double heterozygosity for factor V Leiden and prothrombin G20210A mutations [4, 5] , and patients with antiphospholipid syndrome [6] . Increased levels of blood clotting factor VIII [7, 8] and factor IX [9] have been shown to be associated with the risk of a first and also a recurrent VTE. It is still unclear whether the presence of heritable thrombophilic alterations is significantly associated with a higher risk of VTE recurrence, and results of clinical studies are not consistent. Two recent prospective cohort studies have, in fact, given different results [10, 11] . A recent review [12 ] of studies found that the presence of factor V Leiden or prothrombin G20210A heterozygous mutations, highly prevalent in the general white population, was associated with a significantly increased risk of recurrent VTE. Patients who have suffered from more than one VTE episode have a very high risk of recurrence and warrant indefinite anticoagulation [13] .
Cancer is one of the most important persistent factors associated with VTE. Recurrent VTE events occur more frequently in patients with cancer, either during anticoagulation [14, 15] or after anticoagulation is stopped [1] , and especially in those who receive concurrent chemotherapy [2] . The risk of VTE recurrence is lower if the first thrombotic event was limited to the deep calf veins than if it involved more proximal veins [16] .
Stratification of the risk of recurrence and duration of anticoagulation
The following stratification of patients into groups with increasing risk of VTE recurrence after discontinuation of anticoagulation has recently been proposed [17] : (a) low risk (<5%/year), when the index event was triggered by a reversible major risk factor (major surgery, pelvic or leg trauma, major medical illness) -in these patients the duration of anticoagulation can be as short as 3 months; (b) moderate risk (<10%/year), when the event is associated with weak risk factors (estrogen use, long distance travel, minor trauma) or acquired thrombophilia -in these patients the duration of anticoagulation should be 6 months; (c) high risk (10%/year), unprovoked event with no inherited or acquired thrombophilic condition, or with heterozygous factor V Leiden or prothrombin G20210A mutation -in these patients the duration of anticoagulation should be 6 months or longer on the basis of patient preference and reviewed annually; (d) very high risk (>12%/year), in cases with recurrent unprovoked events with or without thrombophilia, unprovoked events with antithrombin, protein C or protein S deficiency, homozygous factor V Leiden, double heterozygosity, antiphospholipid syndrome, advanced malignancy -extended duration of anticoagulation should be considered in these patients, although no firm evidence is available for this recommendation.
Studies on the effects of different anticoagulant treatment periods
From the above reported risk stratification it can be inferred that many patients who suffered from a first VTE event should receive a prolonged vitamin K antagonist (VKA) treatment; however, it is not known how long is long enough. This therapy is highly effective as it can reduce the risk of recurrence by 90%; however, it is associated with a clinically important risk of major bleeding (ranging in average from 1% to 3% per patient-year of treatment). In recent years a number of clinical studies have investigated the effects of different treatment periods in subjects after a VTE event (for a review see [18] ). Several studies have also shown that the benefit associated with anticoagulation prolongation is not maintained after therapy is discontinued [16, 19, 20] . As a result, it can be concluded that the optimal duration of anticoagulation after a first episode of VTE is still uncertain in many patients.
The value of D-dimer as a risk factor for recurrence of venous thromboembolism D-dimer is a product of lysis of stabilized fibrin-clot that is considered an indirect marker of coagulation activation. Measurement of plasma D-dimer has a well established diagnostic role in acute VTE in symptomatic outpatients because of its high negative predictive value [21] . In 1994 Palareti et al. [22] observed that plasma D-dimer levels tended to increase in some patients with a previous VTE episode when measured during the first 3 months after anticoagulation was stopped. The same authors have since conducted a prospective inception-cohort that included 396 patients with a previous first VTE episode [23] . D-dimer levels were repeatedly measured (VIDAS D-dimer ELISA method, bioMerieux, Marcy l'Etoile, France; normal value 500 ng/ml) at standard times during anticoagulation and after anticoagulation was stopped. Abnormal D-dimer levels were observed in 15.5% of patients on the day of warfarin discontinuation. The rate increased to 40.3% and 46.2% after 1 and 3 months, respectively. The rates of increased D-dimer were higher in patients whose first VTE event was idiopathic or associated with persistent risk factors than in those with transient risk factors. No difference was found according to the duration of previous anticoagulant treatment. The hazard ratio (HR) for recurrence was significantly higher in subjects with abnormal versus normal D-dimer at 3 months (2.45; 95% confidence interval [CI] 1.28-4.53; P < 0.01).
More recently, the same authors investigated the predictive value for recurrent VTE of D-dimer levels measured (VIDAS D-dimer ELISA method) 1 month after anticoagulation interruption in patients with a previous unprovoked event, including both carriers and noncarriers of congenital thrombophilia [11] . A total of 599 patients with a previous VTE episode were examined for D-dimer after warfarin withdrawal and screened for inherited thrombophilic alterations; the latter were detected in 130 patients (21.7%). Altered D-dimer results were associated with a significantly higher recurrence rate in patients with an unprovoked qualifying VTE event (HR ¼ 2.43; 95% CI 1.18-4.61) and especially in those with thrombophilia (HR ¼ 8.34; 95% CI 2.72-17.43). The higher relative risk for recurrence of altered D-dimer was confirmed by multivariate analysis after adjustment for other risk factors.
Eichinger et al. [24] published similar results in the same year. In their prospective study a cohort of 610 patients with a first spontaneous VTE, who had received oral anticoagulants for at least 3 months, entered the study at time of discontinuation of anticoagulation. D-dimer levels were measured (Asserachrom D-dimer, Boehringer Mannheim, Germany; n. v. 250 ng/ml) shortly after discontinuation of oral anticoagulation. The cumulative probability of recurrent VTE at 2 years was 3.7% (95% CI 0.9-6.5%) and 11.5% (95% CI 8.0-15.0%) among patients with normal or abnormal D-dimer, respectively (P ¼ 0.001).
Shivrastava et al. [25 ] have also shown that D-dimer levels have a predictive value for VTE recurrence. They assessed the D-dimer levels (Liatest D-Di; Diagnostica Stago, Asniè res Cedex, France) in 508 idiopathic VTE patients treated for at least 3 months with full-intensity warfarin and who had stopped warfarin for 7 weeks. After blood sampling, the patients were randomized to lowintensity warfarin or placebo and followed for 2.1 years for recurrent VTE. The adjusted HR for recurrent VTE in subjects with elevated D-dimer was 2.0 (95% CI 1.2-3.4) and the annual recurrence incidence was 10.9% in these patients and 2.9% in those with normal values.
Cosmi et al. [26] assessed the predictive value of D-dimer and residual venous obstruction (RVO) in combination for recurrent VTE in a prospective cohort of 400 outpatients after VKA suspension for a first episode of idiopathic proximal deep vein thrombosis (DVT) of the lower limbs during a 2-year follow-up. The recurrence rate was 16.7% in all subjects, 7.9% in subjects with normal D-dimer, 24.9% in subjects with abnormal D-dimer, 14.9% in subjects with absent RVO, and 18.2% in subjects with RVO. The multivariate hazard ratio for recurrence was 3.32 (95% CI 1.78-6.75; P < 0.0001) for abnormal D-dimer and 1.2 (95% CI 0.72-2.07) for RVO. These results indicate that increased D-dimer at 30 AE 10 days after VKA withdrawal is an independent risk factor for recurrent VTE; the persistence of RVO at the time of VKA withdrawal in the presence of abnormal D-dimer does not contribute to the risk of recurrence. D-dimer levels and the persistence of a RVO, alone or in combination, were found to be independent risk factors for VTE recurrence in cancer patients with a first episode of proximal leg DVT followed for 2 years after VKA interruption [27] .
Kuruvilla et al. [28] prospectively examined the natural history of D-dimer results in 152 patients with acute VTE. At 3 months, 13% remained positive, which is consistent with the 15.5% reported by Palareti et al. [23] . Seven patients had recurrent events and all had persistently elevated D-dimers at 1 month. According to the authors, the study suggests that a persistently positive D-dimer result after 1 month of treatment may indicate a higher risk of recurrent venous thromboembolism.
Other authors have investigated the value of D-dimer measured during oral anticoagulation in patients with DVT [29, 30] . Fattorini et al. [30] measured D-dimer (LPIA D-dimer assay, Mitsubishi, Tokyo, Japan) and found that the probability of suffering recurrence was higher in patients whose D-dimer levels were higher during and/or after anticoagulation withdrawal.
D-dimer testing to individualize duration of anticoagulation after a first venous thromboembolism: the Prolong study
The prospective, collaborative, randomized Prolong study has recently been published [31 ] . The study, performed in centers affiliated with the Italian Federation of Thrombosis Centers, aimed to (a) evaluate the safety of withholding VKA in patients with normal D-dimer assessed 1 month after VKA interruption; (b) establish the risk of recurrence in patients with altered D-dimer at that time; and (c) evaluate the protective effect of a resumption of VKA treatment in the patients of the latter group.
Patients aged 18-85 years with a first episode of symptomatic unprovoked VTE (proximal DVT of legs and/or pulmonary embolism), diagnosed by objective testing, after a treatment of at least three months with VKA (international normalized ratio: 2.0-3.0) were included in the study. The presence of antiphospholipid antibody syndrome, antithrombin deficiency, serious liver disease, renal insufficiency (plasma creatinine >2 mg/dl), other indications for anticoagulation or contraindications for such treatment, and limited life expectancy were all exclusion criteria, as were geographical impediments for follow-up. Patients stopped VKA at inclusion in the study and blood sampling for D-dimer assay and thrombophilia tests was performed after 30 AE 10 days. The same method for D-dimer assay was used in all centers: the Clearview Simplify D-dimer assay (Inverness Medical Professional Diagnostics, Bedford, UK and Louisville, CO, USA; kindly provided by the Instrumentation Laboratory company, Milan), a qualitative, fast method, performed on whole blood that was previously shown to perform well in VTE diagnosis [32] . Patients with normal D-dimer did not continue anticoagulation, whereas those with abnormal D-dimer results were randomly assigned either to stop or to resume VKA (international normalized ratio: 2.0-3.0) during the subsequent follow-up period of up to 18 months. All suspected outcome events (recurrent VTE and major bleeding events) and all deaths were evaluated by a blind central adjudication committee.
A total of 627 eligible patients were examined in 30 clinical centers between 13 September 2002 and 31 January 2005. After exclusion of eight patients (three refused to participate in the study and five had a recurrent VTE between VKA discontinuation and the 1-month assignment visit), D-dimer assay was performed in 619 patients: 392 (63.3%) had a normal D-dimer; the remaining 227 with an abnormal D-dimer were randomized to either resume (105) or not resume anticoagulation (122). After randomization 11 patients were excluded because of the presence of lupus anticoagulant (nine) or antithrombin deficiency (two). The analyzed patients included 608 subjects: 385 had normal D-dimer, 120 with abnormal D-dimer were assigned to not resume VKA and 103 had abnormal D-dimer and were randomized to resume VKA; however, nine of the latter refused to do so. The mean duration of follow-up was 1.4 years and 69% of all patients completed the 18 follow-up months.
During follow-up the incidence of recurrent VTE was 15.0% (10.9% patient-years) and 2.9% (2.0% patient-years) in the patients with abnormal D-dimer randomized not to resume or to resume anticoagulation, respectively, and 6.2% (4.4% patient-years) in those with normal D-dimer test. Event rates were significantly higher in patients with an abnormal D-dimer randomized not to resume anticoagulation than in those who resumed VKA (adjusted HR 4.26; 95% CI 1.23-14.6; P ¼ 0.02) or in those with a normal D-dimer (adjusted HR 2.27; 95% CI 1.15-4.46; P ¼ 0.02). No significant interaction was observed between the risk of recurrence in the three comparisons and categories of prespecified baseline variables; however, the number of study subjects was small enough that some clinically important interactions may not have been detectable. No deaths from recurrent VTE or from bleeding events were recorded.
Conclusion
These results confirm that the D-dimer assay is correlated with the individual risk of recurrence after a first VTE episode and may be useful in determining the individual duration of anticoagulation by identifying those who, having altered D-dimer after VKA is stopped, have a high recurrence rate and benefit the most from prolongation of this demanding and risky treatment. The risk/benefit relationship of prolonging anticoagulation in patients with normal D-dimer, who have a significantly lower risk of recurrence, is still uncertain.
Unresolved issues are still present. In the Prolong study elderly patients had altered D-dimer assay more often than the younger ones, and their hazard ratio was not statistically significant. This result is in line with other reports [33] and underlines the hypercoagulability and higher risk of VTE in the elderly. It seems reasonable, however, that quantitative D-dimer assays, by allowing more specific cut-off levels according to the patient's age, may perform better than a qualitative assay. The use of the same qualitative assay was necessary in the collaborative Prolong study to uniformly classify the D-dimer results as either normal or abnormal due to the lack of comparability of quantitative methods routinely used in the clinical laboratories of the participating centers. The possible advantages of an approach based on use of quantitative D-dimer assays has recently been investigated by examining frozen samples obtained from a large portion of patients included in the Prolong study and centralized in the coordinating center. From the preliminary data of this investigation we can anticipate that higher cut-off levels in patients aged over 70 years can markedly improve the predictive performance of D-dimer assays in this subgroup of patients (Legnani, C. et al., unpublished data).
The Prolong study has not provided all the information we need. First of all, five patients experienced VTE events during the interval time between OAT withdrawal and D-dimer measurement. Unfortunately, no information is available on their D-dimer levels (or of the other patients) on the day anticoagulation was stopped. It is therefore impossible to comment on the relationship between D-dimer levels during anticoagulation and early recurrence after interruption. Furthermore, the D-dimer assay was performed only once (1 month after VKA interruption). It is possible that during the subsequent 18 months of follow-up some patients with originally normal D-dimer tests would have had abnormal results on repeat testing, providing a detectable warning sign of recurrent hypercoagulability and increased risk of thrombosis. Repeated D-dimer assays in patients with an originally normal test may be useful in detecting a late hypercoagulability relapse. This should be assessed in future studies. Some of these issues are currently under investigation by the new Prolong II study (ClinicalTrials.gov Identifier: NCT00266045).
